A Phase I, Randomized, Single-Blind, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacodynamics Of AZD8601 After Single Dose Administration to Male Patients With Type II Diabetes Mellitus (T2DM)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs AZD 8601 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 07 Aug 2017 Planned End Date changed from 29 Dec 2017 to 2 Jan 2018.
- 07 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2017 Planned End Date changed from 1 Jul 2017 to 29 Dec 2017.